Many of the new therapies being evaluated in BRCA1 breast cancers, such as poly(ADP-ribose) polymerase (PARP) inhibitors and cisplatin [47,48], are designed to take advantage of the defect in homologous recombination that BRCA1 deficiency causes in these cancers. The gene discussed is BRCA1; the disease is breast carcinoma.